neurostar.com - STIM Company Value to Revenue Ratio

Public company logo of Neuronetics (STIM)

Neuronetics, Inc. (STIM) growth relies on the expansion of NeuroStar systems and an increase in insurance reimbursements. The enterprise value-to-revenue ratio visualizes the market consensus, where 1004.44 represents the latest level. However, high promotion costs and pressure from the pharmaceutical sector limit profitability. Meanwhile, its independence from macroeconomic trends transforms the asset into a reliable defensive solution during recessionary periods.

STIM Neuronetics, Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/19/2026

STIM (NeuroStar): analytical breakdowns and indicator data

Fundamental valuation:Neuronetics, Inc. STIM
Mass-produced product of Neuronetics Inc.

For non-invasive neurostimulation developer Neuronetics, Inc. (STIM), the EV/Sales history reflects the market valuation of its depression treatment technology potential. This metric compares the total enterprise value, adjusted for net debt, against annual sales volume. Such an approach eliminates the impact of leverage, revealing the actual value of operating assets. Amid tight Fed policy, a declining ratio signals multiple compression. This helps investors assess whether they are overpaying for innovation.

Competitor analysis for Neuronetics, Inc.

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple AxoGen, Inc. AXGN|SI-BONE Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Orthofix Medical OFIX|Bioventus Global (BVS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume KIDS (OrthoPediatrics Inc.)|Enterprise Value-to-Revenue Ratio treace.com|Company Value to Revenue Strata Critical Medical Inc (SRTA)|EV/Sales Multiple CARL|RXST - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio clearpointneuro.com CLPT|STXS: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio